Intuitive Surgical Shares Fall 8% on Revised 2026 Growth Outlook

Intuitive Surgical shares fell approximately 8% on 21 October 2026 after the company narrowed its full-year robotic surgery procedure growth forecast. The Intuitive Surgical procedure growth outlook now stands at 14% to 15%, with performance expected near the midpoint, despite a 22% increase in third-quarter revenue.

Intuitive narrows 2026 procedure growth forecast

The company previously projected global procedure growth of 13.5% to 15.5%. Its revised guidance indicates a more cautious assessment of demand for the remainder of 2026.

During an earnings call, Dan Connally, Intuitive’s head of investor relations, identified US insurance changes and competitive pressures in China as factors affecting expectations.

“Our range continues to consider the impact of changes to Affordable Care Act (ACA) premium subsidies on patient behaviour in the US as well as tender volumes and competitive intensity in China, among other factors.”

Third-quarter revenue rises 22%

Intuitive reported third-quarter revenue of about $3.05bn, up 22% year on year and above the $2.91bn analyst consensus, Reuters reported.

Instruments and accessories generated about $1.8bn, the company's largest revenue segment. Systems contributed $769.1m, while services accounted for $482.2m.

Adjusted earnings reached $3 per diluted share. The results reflected continued demand for robotic procedures and equipment despite the narrower annual forecast.

Da Vinci 5 placements support system sales

Worldwide procedures involving the da Vinci and Ion platforms increased approximately 15% year on year during the third quarter.

Intuitive placed 546 da Vinci surgical systems, including 315 da Vinci 5 units.

The US Food and Drug Administration (FDA) cleared da Vinci 5 in March 2024. The platform subsequently received European CE marking for cardiac procedures in September 2026.

CEO Dave Rosa highlighted placements across the company's multi-port, single-port and Ion platforms. Customers performed more than 10,000 procedures daily on average during the quarter.

Shares decline following earnings announcement

Intuitive released its quarterly results after US markets closed on 20 October.

Its Nasdaq-listed shares fell from approximately $438 to $402 at the opening of trading on 21 October, a decline exceeding 8%.

The company had a reported market capitalisation of $154.74bn.

The market reaction reflected concerns about future procedure growth despite increased revenue and surgical system placements.

Robotic surgery market projected to reach $23.6bn

According to GlobalData, the worldwide robotic surgery market is forecast to increase from $12.8bn in 2025 to $23.6bn by 2035.

The forecast represents a compound annual growth rate of 6.3%.

GlobalData also estimated that Intuitive held 48.8% of the US robotic surgical systems market in 2025.

For hospitals, surgical departments and medical equipment distributors, the Intuitive Surgical procedure growth outlook highlights differences between current system demand and expected procedural activity. Medigear.uk covers these developments as robotic surgery manufacturers expand their technology and clinical applications.

Source: Medical Device Network